Naltrexone
Brand names: Naltrexene, Opizone, Vivitrol (extended-release IM — US)
Naltrexone is a long-acting opioid receptor antagonist used as an adjunct in detoxified, formerly opioid-dependent adults to support continued abstinence by blocking the effects of opioids.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It competitively antagonises mu opioid receptors, blocking the euphoric and other effects of exogenous opioids and thereby removing their reinforcing reward.
Prescribing in practice
- The patient must be opioid-free and confirmed abstinent before starting, as giving it too soon precipitates a severe acute withdrawal reaction.
- It blocks opioid analgesia, so alternative pain management is needed and patients carry a heightened overdose risk if they relapse after tolerance has fallen.
- Assess liver function before and during treatment, and use cautiously in hepatic or renal impairment.
Monitoring
Check liver function before starting and periodically during treatment, and monitor abstinence, adherence and engagement with the wider treatment programme.
Counselling the patient
- Do not take any opioids while on this medicine; trying to overcome the block with large doses risks fatal overdose.
- Carry information that you take an opioid blocker in case you need emergency pain relief.
- Use it as part of a structured relapse-prevention programme with psychological support.
Evidence & guidelines
NICE recommends naltrexone as an option to help maintain abstinence in detoxified, formerly opioid-dependent people who are motivated to remain opioid-free.
Reference: NICE NG58 Opioid Dependence; COMBINE Study (Anton et al, JAMA 2006); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) Pain Assessment and Management · Pain Management
- Finnegan Neonatal Abstinence Scoring Tool (FNAST) · Neonatal Abstinence Syndrome
- Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale · Neuromuscular
- Glasgow Outcome Scale — Extended (GOSE) · TBI Outcome
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185